论文部分内容阅读
作者回顾了药品安全委员会收到的有关使用两种血管紧张素转换酶(ACE)抑制剂巯甲丙脯酸(CPT)和苯脂丙脯酸(ENP)发生血管性水肿和荨麻疹的报告.在销售CPT5年8个月和ENP1年期间,药品安全委员会收到有关怀疑这两种药物不良反应的所有报告,作者均进行了审查.ENP:13例发生血管性水肿,其中1例还伴发荨麻疹.6例于首剂服药后出现反应,其余7例在5天内发生反应,1例患者服药2次,每次服药后均发生急性反应,但无正规的再激发实验报道.12例患者在停药后1～2天内血管性水肿消除,2例使用了
The authors review reports received by the CGF on angioedema and urticaria using two angiotensin-converting enzyme (ACE) inhibitors, captopril (CPT) and phenylephrine (ENP). During the 8 months of CPT5 sales and ENP1 years, all reports received by the CFTC on suspected adverse reactions to these two drugs were reviewed by the authors.ENP: Vascular edema occurred in 13 patients, of which 1 was accompanied by Urticaria .6 cases after the first dose of the reaction occurred, the remaining seven cases in 5 days reaction occurred, 1 patient took 2 times, each time after taking an acute response, but no formal re-excitation experiment reported.12 patients Vaginal edema was eliminated within 1-2 days after discontinuation, and 2 cases were used